Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F23%3A00570226" target="_blank" >RIV/67985823:_____/23:00570226 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/23:00083716 RIV/00216208:11130/23:10448594 RIV/61989592:15110/23:73618651 RIV/00098892:_____/23:10157833 RIV/00064203:_____/23:10448594
Result on the web
<a href="https://journals.lww.com/jhypertension/Fulltext/2023/01000/Endothelin_type_A_receptor_blockade_attenuates.11.aspx" target="_blank" >https://journals.lww.com/jhypertension/Fulltext/2023/01000/Endothelin_type_A_receptor_blockade_attenuates.11.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HJH.0000000000003307" target="_blank" >10.1097/HJH.0000000000003307</a>
Alternative languages
Result language
angličtina
Original language name
Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension
Original language description
Objective:Evaluation of the effect of endothelin type A (ETA) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension.Methods:Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ETA receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied, the follow-up period was 20 weeks.Results:Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ETA receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts.Conclusion:The treatment with ETA receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ETA receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Hypertension
ISSN
0263-6352
e-ISSN
1473-5598
Volume of the periodical
41
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
16
Pages from-to
99-114
UT code for WoS article
000921029000013
EID of the result in the Scopus database
2-s2.0-85143180046